Patents by Inventor Kari Alitalo

Kari Alitalo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Patent number: 8637262
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 28, 2014
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Vladimir Joukov
  • Method of enhancing the acceptance and/or healing of a skin graft
    Patent number: 8461109
    Abstract: The invention also relates to a method for of enhancing the acceptance and/or healing of a skin graft in a subject comprising stimulating angiogenesis and lymphangiogenesis with an effective amount of an isolated VEGF-D polypeptide.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: June 11, 2013
    Assignee: Vegenics Pty Limited
    Inventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
  • Use of VEGF-D gene to prevent restenosis
    Patent number: 8455453
    Abstract: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: June 4, 2013
    Assignee: Vegenics Pty Ltd
    Inventors: Kari Alitalo, Seppo Ylä-Herttuala, Mikko O. Hiltunen, Markku M. Jeltsch, Marc G. Achen
  • Methods of making VEGF-D polypeptides
    Patent number: 8445234
    Abstract: Disclosed herein are methods of making a VEGF-D polypeptide comprising the steps of culturing a host cell transformed or transfected with a vector comprising a nucleic acid sequence encoding the VEGF-D polypeptide operably associated with a promoter sequence such that the nucleic acid sequence encoding the VEGF-D polypeptide is expressed; and isolating the VEGF-D polypeptide from the host cell or from the growth medium in which said host cell is cultured.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: May 21, 2013
    Assignee: Vengenics Pty Limited
    Inventors: Marc G. Achen, Stephen A. Stacker, Kari Alitalo, Andrew F. Wilks
  • Methods of screening for neoplastic disease states
    Patent number: 8444957
    Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: May 21, 2013
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Arja Kaipainen, Rejia Valtola, Lolla Jussila
  • BIOMARKER FOR SENSITIVITY TO THERAPY WITH A NOTCH INHIBITOR
    Publication number: 20130039930
    Abstract: Described herein are materials and methods for identifying subjects that would benefit from Notch-targeted therapy.
    Type: Application
    Filed: June 8, 2012
    Publication date: February 14, 2013
    Inventors: Kari Alitalo, Andrey Anisimov, Masahiro Yamamoto
  • Method of treatment for lymphedema comprising administering a polynucleotide encoding VEGF-D
    Patent number: 8357669
    Abstract: The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: January 22, 2013
    Assignees: Vegenics Pty Limited, University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Robert E. Ferrell, Kari Alitalo, David N. Finegold, Marika Karkkainen
  • GROWTH FACTOR
    Publication number: 20120322105
    Abstract: VEGF-D, new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Application
    Filed: May 17, 2012
    Publication date: December 20, 2012
    Applicant: Vegenics PTY Limited
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
  • Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas
    Publication number: 20120270781
    Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
    Type: Application
    Filed: April 17, 2012
    Publication date: October 25, 2012
    Applicant: VEGENICS PTY LIMITED
    Inventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Patent number: 8282931
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: October 9, 2012
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Vladimir Joukov
  • Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
    Patent number: 8278098
    Abstract: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: October 2, 2012
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Markku M. Jeltsch
  • Methods of stimulating wound healing by administration of vascular endothelial growth factor D (VEGF-D)
    Patent number: 8227410
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: July 24, 2012
    Assignee: Vegenics Pty Limited
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
  • Materials and Methods for the Treatment of Hypertension
    Publication number: 20120141424
    Abstract: The present invention is directed to materials and methods for the treatment of hypertension and ischemia comprising administering at least one therapeutic agent selected from the group consisting of vascular endothelial growth factor-C product and vascular endothelial growth factor-D product, and optionally, when treating hypertension, a standard of care anti-hypertensive agent.
    Type: Application
    Filed: January 7, 2010
    Publication date: June 7, 2012
    Applicant: VEGENICS PTY LIMITED
    Inventors: Kari Alitalo, Tuomas Tammela, Georgia Zarkada, Denis Tvorogov
  • AUTOLOGOUS LYMPH NODE TRANSFER IN COMBINATION WITH VEGF-C OR VEGF-D GROWTH FACTOR THERAPY TO TREAT SECONDARY LYMPHEDEMA AND TO IMPROVE RECONSTRUCTIVE SURGERY
    Publication number: 20120125348
    Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.
    Type: Application
    Filed: October 21, 2011
    Publication date: May 24, 2012
    Applicant: VEGENICS LIMITED
    Inventors: KARI ALITALO, Anne Saaristo, Tuomas Tammela
  • MODIFIED VEGF-A WITH IMPROVED ANGIOGENIC PROPERTIES
    Publication number: 20120071406
    Abstract: The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand. The chimeric molecules of the present invention retain VEGFR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A.
    Type: Application
    Filed: August 19, 2011
    Publication date: March 22, 2012
    Applicant: VEGENICS PTY LIMITED
    Inventors: KARI ALITALO, Tuomas Tammela, Salla Keskitalo, Katri Pajusola, Markku M. Jeltsch, Seppo Yla-Herttuala, Terhi Karpanen, Ulf Eriksson, Marko J. T. Uutela
  • SCREENING AND THERAPY FOR LYMPHATIC DISORDERS INVOLVING THE FLT4 RECEPTOR TYROSINE KINASE (VEGFR-3)
    Publication number: 20120010276
    Abstract: The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 12, 2012
    Applicants: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, VEGENICS PTY LTD
    Inventors: ROBERT E. FERRELL, Kari Alitalo, David N. Finegold, Marika Karkkainen
  • Vascular Endothelial Growth Factor D (VEGF-D) Antibodies and Vectors, and Methods of Uses
    Publication number: 20110281799
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Application
    Filed: March 16, 2011
    Publication date: November 17, 2011
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
  • Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas
    Publication number: 20110269146
    Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
    Type: Application
    Filed: November 5, 2010
    Publication date: November 3, 2011
    Applicant: VEGENICS LIMITED
    Inventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
  • Growth Factor Binding Constructs Materials and Methods
    Publication number: 20110243912
    Abstract: The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.
    Type: Application
    Filed: December 17, 2010
    Publication date: October 6, 2011
    Applicant: VEGENICS LIMITED
    Inventors: Kari Alitalo, Markku Michael Jeltsch
  • Materials and methods for colorectal cancer screening, diagnosis and therapy
    Patent number: 8029984
    Abstract: The invention provides materials and methods for colorectal cancer screening, diagnosis, and therapy.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: October 4, 2011
    Assignee: Licentia, Ltd.
    Inventors: Kari Alitalo, Tatiana Petrova, Antti Nykanen